RESIST-2: 2nd-line ART for HIV-2 Infection
Condition: HIV-2 Infection Interventions: Diagnostic Test: HIV-2 Genotypic Drug Resistance Testing using DBS; Drug: 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID); Drug: 2nd line ART (Tenofovir DF 300mg QD + La mividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID ); Drug: 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID) Sponsors: University of Washington; Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal; Centre de Sante de Ziguinchor, Casamance, Senegal; Janssen Pharmaceutica; Merck Sharp & Dohme Corp.; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Infectious Diseases | Isentress | Kaletra | Norvir | Prezista | Research | Senegal Health | Truvada | Viread